GAITHERSBURG, MD. — Findings from the JUPITER study were persuasive enough to convince a Food and Drug Administration advisory panel that the benefits of rosuvastatin for the primary prevention of cardiovascular disease outweighed the risks in a new target population.
PREVIEW